In October of 2014, The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Committee (CPGC) endorsed the CAP / IASLC / AMP guideline for EGFR and
ALK molecular testing.
Not exact matches
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (
ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any
molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
The updated guideline will include new recommendations for
ALK testing by IHC,
ALK - EGFR resistance, and a number of emerging target
molecular targets which will include, but is not limited to, ROS1, MET, ERBB2, RET, NTRK1.
BETHESDA, MD. — June 28, 2016 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for
Molecular Pathology (AMP) announced today the open comment period for the revised evidence - based guideline, «
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and
ALK Tyrosine Kinase Inhibitors.»